vs
MANGOCEUTICALS, INC.（MGRX）与Sotera Health Co（SHC）财务数据对比。点击上方公司名可切换其他公司
Sotera Health Co的季度营收约是MANGOCEUTICALS, INC.的3215.8倍（$303.4M vs $94.4K）。Sotera Health Co净利率更高（11.5% vs -2935.1%，领先2946.6%）。Sotera Health Co同比增速更快（4.6% vs -10.3%）。过去两年Sotera Health Co的营收复合增速更高（10.6% vs -33.6%）
MANGOCEUTICALS INC是一家专注男士健康护理的企业，研发销售经科学验证的膳食补充剂、男士护肤及护发产品，主要面向美国市场，通过直营电商平台及精选零售渠道为成年男性提供便捷透明的健康护理解决方案。
Sotera Health Co是全球领先的医疗安全解决方案提供商，面向医疗器械厂商、制药企业、食品及消费品公司提供灭菌服务、实验室分析检测与合规咨询支持，帮助客户满足监管要求，保障上市产品的使用安全。
MGRX vs SHC — 直观对比
营收规模更大
SHC
是对方的3215.8倍
$94.4K
营收增速更快
SHC
高出14.9%
-10.3%
净利率更高
SHC
高出2946.6%
-2935.1%
两年增速更快
SHC
近两年复合增速
-33.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $94.4K | $303.4M |
| 净利润 | $-2.8M | $34.8M |
| 毛利率 | 50.3% | 54.7% |
| 营业利润率 | -389.7% | 23.2% |
| 净利率 | -2935.1% | 11.5% |
| 营收同比 | -10.3% | 4.6% |
| 净利润同比 | -42.1% | 182.8% |
| 每股收益（稀释后） | $0.38 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MGRXSHC
| Q4 25 | $94.4K | $303.4M | ||
| Q3 25 | $84.2K | $311.3M | ||
| Q2 25 | $168.1K | $294.3M | ||
| Q1 25 | $109.3K | $254.5M | ||
| Q4 24 | $105.2K | $290.2M | ||
| Q3 24 | $133.4K | $285.5M | ||
| Q2 24 | $163.2K | $276.6M | ||
| Q1 24 | $214.1K | $248.2M |
净利润MGRXSHC
| Q4 25 | $-2.8M | $34.8M | ||
| Q3 25 | $-7.6M | $48.4M | ||
| Q2 25 | $-5.4M | $8.0M | ||
| Q1 25 | $-4.8M | $-13.3M | ||
| Q4 24 | $-1.9M | $12.3M | ||
| Q3 24 | $-2.0M | $17.0M | ||
| Q2 24 | $-2.4M | $8.8M | ||
| Q1 24 | $-2.4M | $6.3M |
毛利率MGRXSHC
| Q4 25 | 50.3% | 54.7% | ||
| Q3 25 | 60.4% | 57.0% | ||
| Q2 25 | 53.5% | 56.6% | ||
| Q1 25 | 56.8% | 53.2% | ||
| Q4 24 | 76.1% | 56.6% | ||
| Q3 24 | 62.0% | 55.4% | ||
| Q2 24 | 42.8% | 55.2% | ||
| Q1 24 | 68.8% | 51.2% |
营业利润率MGRXSHC
| Q4 25 | -389.7% | 23.2% | ||
| Q3 25 | -8953.5% | 23.4% | ||
| Q2 25 | -3134.0% | 6.4% | ||
| Q1 25 | -4440.0% | -5.8% | ||
| Q4 24 | -1594.0% | 30.0% | ||
| Q3 24 | -1318.2% | 28.2% | ||
| Q2 24 | -1329.1% | 27.8% | ||
| Q1 24 | -1105.9% | 21.4% |
净利率MGRXSHC
| Q4 25 | -2935.1% | 11.5% | ||
| Q3 25 | -9042.8% | 15.5% | ||
| Q2 25 | -3221.6% | 2.7% | ||
| Q1 25 | -4427.4% | -5.2% | ||
| Q4 24 | -1851.2% | 4.2% | ||
| Q3 24 | -1499.0% | 6.0% | ||
| Q2 24 | -1465.4% | 3.2% | ||
| Q1 24 | -1105.9% | 2.5% |
每股收益（稀释后）MGRXSHC
| Q4 25 | $0.38 | $0.12 | ||
| Q3 25 | $-0.69 | $0.17 | ||
| Q2 25 | $-0.57 | $0.03 | ||
| Q1 25 | $-1.29 | $-0.05 | ||
| Q4 24 | $-0.79 | $0.05 | ||
| Q3 24 | $-1.14 | $0.06 | ||
| Q2 24 | $-1.37 | $0.03 | ||
| Q1 24 | $-1.50 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5M | $344.6M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | $15.2M | $606.0M |
| 总资产 | $16.1M | $3.3B |
| 负债/权益比越低杠杆越低 | — | 3.53× |
8季度趋势，按日历期对齐
现金及短期投资MGRXSHC
| Q4 25 | $1.5M | $344.6M | ||
| Q3 25 | $481.3K | $299.2M | ||
| Q2 25 | $101.0K | $332.4M | ||
| Q1 25 | $76.5K | $304.4M | ||
| Q4 24 | $58.7K | $277.2M | ||
| Q3 24 | $73.9K | $306.7M | ||
| Q2 24 | $490.2K | $246.1M | ||
| Q1 24 | $15.3K | $261.1M |
总债务MGRXSHC
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
股东权益MGRXSHC
| Q4 25 | $15.2M | $606.0M | ||
| Q3 25 | $15.7M | $550.5M | ||
| Q2 25 | $19.2M | $511.3M | ||
| Q1 25 | $20.3M | $414.1M | ||
| Q4 24 | $13.9M | $404.9M | ||
| Q3 24 | $13.4M | $470.2M | ||
| Q2 24 | $13.8M | $422.8M | ||
| Q1 24 | $-958.4K | $429.4M |
总资产MGRXSHC
| Q4 25 | $16.1M | $3.3B | ||
| Q3 25 | $16.5M | $3.2B | ||
| Q2 25 | $20.8M | $3.2B | ||
| Q1 25 | $21.8M | $3.1B | ||
| Q4 24 | $15.4M | $3.1B | ||
| Q3 24 | $14.8M | $3.1B | ||
| Q2 24 | $15.2M | $3.1B | ||
| Q1 24 | $301.4K | $3.1B |
负债/权益比MGRXSHC
| Q4 25 | — | 3.53× | ||
| Q3 25 | — | 3.89× | ||
| Q2 25 | — | 4.34× | ||
| Q1 25 | — | 5.36× | ||
| Q4 24 | — | 5.49× | ||
| Q3 24 | — | 4.73× | ||
| Q2 24 | — | 5.26× | ||
| Q1 24 | — | 5.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $103.1M |
| 自由现金流经营现金流 - 资本支出 | — | $52.4M |
| 自由现金流率自由现金流/营收 | — | 17.3% |
| 资本支出强度资本支出/营收 | — | 16.7% |
| 现金转化率经营现金流/净利润 | — | 2.96× |
| 过去12个月自由现金流最近4个季度 | — | $149.2M |
8季度趋势，按日历期对齐
经营现金流MGRXSHC
| Q4 25 | $-1.1M | $103.1M | ||
| Q3 25 | $-1.2M | $71.2M | ||
| Q2 25 | $-1.3M | $57.4M | ||
| Q1 25 | $-2.3M | $55.5M | ||
| Q4 24 | $-1.1M | $55.7M | ||
| Q3 24 | $-1.2M | $97.5M | ||
| Q2 24 | $-1.6M | $61.3M | ||
| Q1 24 | $-991.1K | $9.7M |
自由现金流MGRXSHC
| Q4 25 | — | $52.4M | ||
| Q3 25 | — | $35.0M | ||
| Q2 25 | — | $26.2M | ||
| Q1 25 | — | $35.6M | ||
| Q4 24 | — | $-10.2M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | — | $19.4M | ||
| Q1 24 | — | $-25.2M |
自由现金流率MGRXSHC
| Q4 25 | — | 17.3% | ||
| Q3 25 | — | 11.2% | ||
| Q2 25 | — | 8.9% | ||
| Q1 25 | — | 14.0% | ||
| Q4 24 | — | -3.5% | ||
| Q3 24 | — | 21.4% | ||
| Q2 24 | — | 7.0% | ||
| Q1 24 | — | -10.2% |
资本支出强度MGRXSHC
| Q4 25 | — | 16.7% | ||
| Q3 25 | — | 11.6% | ||
| Q2 25 | — | 10.6% | ||
| Q1 25 | — | 7.8% | ||
| Q4 24 | — | 22.7% | ||
| Q3 24 | — | 12.7% | ||
| Q2 24 | — | 15.2% | ||
| Q1 24 | — | 14.1% |
现金转化率MGRXSHC
| Q4 25 | — | 2.96× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 7.21× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.52× | ||
| Q3 24 | — | 5.73× | ||
| Q2 24 | — | 7.00× | ||
| Q1 24 | — | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MGRX
暂无分部数据
SHC
| Transferred At Point In Time | $198.4M | 65% |
| Nelson Labs | $55.2M | 18% |
| Nordion | $49.8M | 16% |
